{"eventGroups":[{"description":"Patients received melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also received dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients underwent autologous hematopoietic stem cell transplant.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"title":"Melphalan, Bortezomib, Autologous Transplant"}],"frequencyThreshold":"0","timeFrame":"Patients were assessed for adverse events for approximately 1 year until the study was terminated."}